The use of antihypertension in hypertension patients with chronic kidney failure at the Universitas Gadjah Mada (UGM) Academic Hospital, Yogyakarta

  • Syifa Indi Wijaya Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
  • Anggraini Citra Ryshang Bathari Department of Pharmacy, Universitas Gadjah Mada Academic Hospital, Yogyakarta
  • Chairun Wiedyaningsih Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
Keywords: antihypertension, hypertension, chronic kidney failure, rational drugs use, health insurance


According to the 2018 Indonesian Basic Health Research data, the prevalence of hypertension in the Yogyakarta Special Region (11.0%) is higher than the national average of 8.8%. Hypertension with chronic kidney failure is currently a prevalent and increasing issue. This study aimed to investigate the pattern and rationality of antihypertensive use in hypertension patients with chronic kidney failure (CKF) participating in the National Health Insurance (Jaminan Kesehatan Nasional/JKN) program at Universitas Gadjah Mada (UGM) Academic Hospital period of 2020 to 2022. The study was conducted using quantitative descriptive non-experimental methods. Data collection was carried out retrospectively through medical records of patients diagnosed with hypertension with CKF (ICD I12.0). Samples were selected using purposive techniques and analyzed by comparing the suitability of drug selection with standard hypertension therapy with CKF based on JNC 8 and NKF-K/DOQI, including the rationality of their use. A total of 68 patients over the age of 18 were used as samples. The The majority of drug groupsresults showed that a combination of 2 drugs is more dominant (52.9%) compared to monotherapy (29.4%) and a combination of 3 drugs (17.6%). The majority of drug groups used were angiotensin receptor blockers (ARBs), especially candesartan (45%). ARB and calcium channel blockers (CCB), especially candesartan+amlodipin (50%), and ARB +CCB+diuretic, especially andesartan +amlodipine + furosemide (33%).. The rationality of drug use showed that 66.2% in the right indications, 89.7% the right drugs, 100% in the right patients and 85% the right doses. Therefore, health workers still need to make efforts to encourage rational drug use.


World Health Organization. Hypertension [Internet]. [cited 2023 Oct 28]. Available from:

Kemenkes RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementrian Kesehat RI. 2018;53(9):1689-99.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet [Internet]. 2017;389(10064):37-55. Available from:

Kemenkes RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 Tentang Standar Pelayanan Kefarmasian di Rumah sakit. Kementeri Kesehat Republik Indones. 2016;

Kemenkes RI. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/1970/2022 Tentang Perubahan Atas Keputusan Menteri Kesehatan Nomor Hk.01.07/Menkes/6485/2021 Tentang Formularium Nasional. Kementeri Kesehat Republik Indones [Internet]. 2022;2021:4-92. Available from: No. HK.01.07-MENKES-1970-2022 tentang Perubahan atas Formularium Nasional.pdf

Tuloli TS, Madania M, Mustapa MA, Tuli EP. Evaluasi Penggunaan Obat Pada Pasien Gagal Ginjal Kronik Yang Menjalani Hemodialisis Di Rsud Toto Kabila Periode 2017-2018. Parapemikir J Ilm Farm. 2019;8(2):25.

Ellen S. Slovin's Formula Sampling Techniques [Internet]. [cited 2023 Oct 30]. Available from:

Schmieder S. JNC 8 Hypertension Guidline Algorithm. St Cl Comput High - Technol Law J [Internet]. 2004;21(1):163-234. Available from:

National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease [Internet]. 2004 [cited 2023 Nov 6]. Available from:

Dyussenbayev A. Age Periods Of Human Life. Adv Soc Sci Res J [Internet]. 2017;4(6):258-63. Available from:

Lacy CF, Amstrong LL, Goldman MP, Lance LL. Drug Information Handbook: A Comprehensive aaaaaresource for All Clinicians and Healthcare Professionals (Lexi-Comp's Drug Reference Handbooks). Vol. 17, Lexi-Comp Inc. 2009.

Connelly PJ, Currie G, Delles C. Sex Differences in the Prevalence, Outcomes and Management of Hypertension. Curr Hypertens Rep [Internet]. 2022;24(6):185-92. Available from:

Weldegiorgis M, Woodward M. The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis. BMC Nephrol. 2020;21(506):1-9.

Murphy D, Mcculloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al. Trends in prevalence of chronic kidney disease in the United States for the Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team HHS Public Access. Ann Intern Med [Internet]. 2016;165(7):473-81. Available from:

Albertus P, Morgenstern H, Robinson B SR. Risk of ESRD in the United States. Am J Kidney Dis [Internet]. 2016;68(6):862-72. Available from: lifetime cumulative incidences of,%25-6.43%25) for Hispanics.

Chang PY, Chien LN, Lin YF, Wu MS, Chiu WT, Chiou HY. Risk factors of gender for renal progression in patients with early chronic kidney disease. Med (United States). 2016;95(30).

Haller H. Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract. 2008;62(5):781-90.

Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension Clinical Practice Guidelines for the Management of Hypertension in the Comm. J Clin Hypertens. 2014;16(1):14-26.

Laurent S, Boutouyrie P. Arterial Stiffness and Hypertension in the Elderly. Front Cardiovasc Med. 2020;7(October):1-13.

Kohn JC, Lampi MC, Reinhart-King CA. Age-related vascular stiffening: Causes and consequences. Front Genet. 2015;6(MAR):1-17.

Erfanpoor S, Etemad K, Kazempour S, Hadaegh F, Hasani J, Azizi F, et al. Diabetes, hypertension, and incidence of chronic kidney disease: Is there any multiplicative or additive interaction? Int J Endocrinol Metab. 2021;19(1):1-8.

Pugh D, Gallacher PJ, Dhaun N. Management of Hypertension in Chronic Kidney Disease. Drugs [Internet]. 2019;79(4):365-79. Available from:

Hebert SA, Ibrahim HN. Hypertension Management in Patients with Chronic Kidney Disease. Methodist Debakey Cardiovasc J. 2022;18(4):41-9.

Polychronopoulou E, Wuerzner G, Burnier M. How do I manage hypertension in patients with advanced chronic kidney disease not on dialysis? Perspectives from clinical practice. Vasc Health Risk Manag. 2021;17:1-11.

Palmer BF, Fenves AZ. Optimizing Blood Pressure Control in Patients with Chronic Kidney Disease. Baylor Univ Med Cent Proc. 2010;23(3):239-45.

Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis. Lancet [Internet]. 2015;385(9982):2047-56. Available from:

Lacourcie Y, Asmar R. A Comparison of the Efficacy and Duration of Action of Candesartan Cilexetil and Losartan as Assessed by Clinic and Ambulatory Blood Pressure After a Missed Dose, in Truly Hypertensive Patients. Am J Hypertens. 1999;12(12):1181-7.

Meredith P. Achieving quality 24-h blood pressure control with candesartan cilexetil. Blood Press Suppl. 2000;9(1):23-6.

Philipp T, Martinez F, Geiger H, Moulin B, Mourad G, Schmieder R, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: Results from SECRET. Nephrol Dial Transplant. 2010;25(3):967-76.

Guerrero-García C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs Context. 2018;7:1-9.

Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens [Internet]. 2010;4(1):42-50. Available from:

Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetol Metab Syndr [Internet]. 2010;2(44):1-11. Available from:

Mancia G, Rea F, Corrao G, Grassi G. Two-Drug Combinations as First-Step Antihypertensive Treatment. Circ Res. 2019;124(7):1113-23.

Neutel JM. Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management. Am J Hypertens. 1999;12(8 SUPPL. 1):73-9.

Moser M, Black HR. The Role of Combination Therapy in the Treatment of Hypertension. Am J Hypertens. 1998;11:73S-78S.

Burnier M, Lin S, Ruilope L, Bader G, Durg S, Brunel P. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Blood Press [Internet]. 2019;28(6):358-74. Available from:

Denker MG, Cohen DL. Antihypertensive Medications in End-Stage Renal Disease. Semin Dial. 2015;28(4):330-6.

Kumolosasi E, Ng W Bin, Aziz SAA. Effectiveness of antihypertensive drugs in hypertensive patients with end stage renal failure. Med J Malaysia. 2012;67(4):379-85.

Williams AD, Fassett RG, Howden EJ, Coombes JS. Effect of lifestyle modifications on patients with chronic kidney disease [Internet]. Goldsmith DJ, Turner NN, Turner NN, Lameire N, Goldsmith DJ, Winearls CG, et al., editors. Oxford Textbook of Clinical Nephrology. Oxford University Press; 2015. p. 824-9. Available from:

Ritz E, Schwenger V. Lifestyle modification and progressive renal failure. Nephrology. 2005;10(4):387-92.

Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. A combination of healthy lifestyle factors is associated with a decreased incidence of chronic kidney disease: a population-based cohort study. Hypertens Res. 2013;36(4):328-33.